Literature DB >> 21567116

Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock.

Jerome Aboab1, Veronique Sebille, Mercé Jourdain, Jacques Mangalaboyi, Miloud Gharbi, Arnaud Mansart, Djillali Annane.   

Abstract

PURPOSE: The aim of this experimental study is to investigate cardiovascular tolerance of blockade of beta-adrenergic receptors in an endotoxin model.
DESIGN: Prospective, randomized, controlled study.
SETTING: Animal laboratory in a university medical center.
METHODS: Ten anesthetized, mechanically ventilated pigs were challenged with intravenous lipopolysaccharide (LPS) to achieve a status of profound hypodynamic shock. Systemic and pulmonary hemodynamics and cardiac output were continuously monitored throughout the 5-h study period, and blood samples were taken at baseline (T - 30 min), 1 h from the beginning of LPS infusion (T + 60 min), and every 2 h (T + 180 min and T + 300 min). Animals were randomly assigned to continuous intravenous esmolol infusion titrated to decrease heart rate by 20% or isotonic saline.
RESULTS: Esmolol decreased heart rate by 20%, while in the saline group, heart rate increased by 7% and 22% at T + 180 min and T + 300 min, respectively (p < 0.001). In esmolol-treated animals, cardiac index decreased by 9% at T + 180 min and by 2% at T + 300 min, and in controls by 14% at T + 180 min and by 27% at T + 300 min (p = 0.870). In esmolol-treated animals, median (interquartile range, IQR) stroke index was 31 (6) and 47 (11) ml/min/m(2) at T + 180 min and T + 300 min, respectively, and decreased steadily from 45 (20) to 18 (13) ml/min/m(2) in controls (p = 0.030). There were no significant differences between groups for any other hemodynamics variables, except for systemic vascular resistance (SVR) (p = 0.017).
CONCLUSIONS: In large animals with endotoxemic shock, continuous infusion of esmolol, a selective beta-1 adrenergic blocker, titrated to decrease heart rate by 20%, was well tolerated and may offset LPS-induced cardiac dysfunction by a preload positive effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567116     DOI: 10.1007/s00134-011-2236-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  26 in total

Review 1.  Mechanisms and models in heart failure: the biomechanical model and beyond.

Authors:  Douglas L Mann; Michael R Bristow
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

2.  Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation.

Authors:  M Jourdain; O Carrette; A Tournoys; F Fourrier; C Mizon; J Mangalaboyi; J Goudemand; J Mizon; C Chopin
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

3.  The treatment of endotoxin shock by beta adrenergic blockade.

Authors:  J L Berk; J F Hagen; W H Beyer; M J Gerber; G R Dochat
Journal:  Ann Surg       Date:  1969-01       Impact factor: 12.969

4.  Body surface area of female swine.

Authors:  K W Kelley; S E Curtis; G T Marzan; H M Karara; C R Anderson
Journal:  J Anim Sci       Date:  1973-05       Impact factor: 3.159

5.  Reversal of catabolism by beta-blockade after severe burns.

Authors:  D N Herndon; D W Hart; S E Wolf; D L Chinkes; R R Wolfe
Journal:  N Engl J Med       Date:  2001-10-25       Impact factor: 91.245

Review 6.  Septic shock.

Authors:  Djillali Annane; Eric Bellissant; Jean-Marc Cavaillon
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

7.  Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.

Authors:  P J Devereaux; Homer Yang; Salim Yusuf; Gordon Guyatt; Kate Leslie; Juan Carlos Villar; Denis Xavier; Susan Chrolavicius; Launi Greenspan; Janice Pogue; Prem Pais; Lisheng Liu; Shouchun Xu; German Málaga; Alvaro Avezum; Matthew Chan; Victor M Montori; Mike Jacka; Peter Choi
Journal:  Lancet       Date:  2008-05-12       Impact factor: 79.321

8.  Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.

Authors:  C Volz-Zang; B Eckrich; P Jahn; B Schneidrowski; B Schulte; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 9.  Bench-to-bedside review: Beta-adrenergic modulation in sepsis.

Authors:  Etienne de Montmollin; Jerome Aboab; Arnaud Mansart; Djillali Annane
Journal:  Crit Care       Date:  2009-10-23       Impact factor: 9.097

10.  Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum.

Authors:  A Kumar; V Thota; L Dee; J Olson; E Uretz; J E Parrillo
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  25 in total

Review 1.  Heart failure and sepsis: practical recommendations for the optimal management.

Authors:  Angelos Arfaras-Melainis; Eftihia Polyzogopoulou; Filippos Triposkiadis; Andrew Xanthopoulos; Ignatios Ikonomidis; Alexander Mebazaa; John Parissis
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

2.  Does intravenous landiolol, a β1-adrenergic blocker, affect stroke volume variation?

Authors:  Zen'ichiro Wajima; Toshiya Shiga; Kazuyuki Imanaga; Tetsuo Inoue
Journal:  J Anesth       Date:  2013-05-08       Impact factor: 2.078

3.  Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock.

Authors:  Martin Balik; Jan Rulisek; Pavel Leden; Michal Zakharchenko; Michal Otahal; Hana Bartakova; Josef Korinek
Journal:  Wien Klin Wochenschr       Date:  2012-07-20       Impact factor: 1.704

4.  Beta-blockers in septic shock: a magnifying glass on the relation heart vessel.

Authors:  Calypso Mathieu; Laurent Zieleskiewicz; Marc Leone
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 5.  Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum.

Authors:  Davide Tommaso Andreis; Mervyn Singer
Journal:  Intensive Care Med       Date:  2016-02-12       Impact factor: 17.440

Review 6.  β-Blockade use for Traumatic Injuries and Immunomodulation: A Review of Proposed Mechanisms and Clinical Evidence.

Authors:  Tyler J Loftus; Philip A Efron; Lyle L Moldawer; Alicia M Mohr
Journal:  Shock       Date:  2016-10       Impact factor: 3.454

7.  Respective impact of lowering body temperature and heart rate on mortality in septic shock: mediation analysis of a randomized trial.

Authors:  Frédérique Schortgen; Anaïs Charles-Nelson; Lila Bouadma; Geoffray Bizouard; Laurent Brochard; Sandrine Katsahian
Journal:  Intensive Care Med       Date:  2015-07-23       Impact factor: 17.440

Review 8.  The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review.

Authors:  Marta Carrara; Manuela Ferrario; Bernardo Bollen Pinto; Antoine Herpain
Journal:  Ann Intensive Care       Date:  2021-05-17       Impact factor: 6.925

9.  Year in review in Intensive Care Medicine 2011: I. Nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals.

Authors:  Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-01-04       Impact factor: 17.440

10.  β-blockers in critically ill patients: from physiology to clinical evidence.

Authors:  Silvia Coppola; Sara Froio; Davide Chiumello
Journal:  Crit Care       Date:  2015-03-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.